Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation)

Ostinelli, Edoardo G; Jajawi, Salwan; Spyridi, Styliani; Sayal, Kamlaj; Jayaram, Mahesh

doi:10.1002/14651858.cd008074.pub2

Cited by 25 publications

(43 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After the first month, the patient is discharged and AOM is administered monthly thereafter. In fact, we found repeated administration of 9.75 aripiprazole IM to be effective in treating acute psychomotor agitation in acutely psychotic patients (83); this formulation has shown anti-aggressive effects in psychosis-elicited aggression, although the quality of evidence of the studies considered in this systematic review was quite poor (84).…”

Section: Other Issuesmentioning

confidence: 89%

Aripiprazole Long-Acting Injection During First Episode Schizophrenia—An Exploratory Analysis

Giordano¹,

Tomassini²,

Cuomo

et al. 2020

Front. Psychiatry

View full text Add to dashboard Cite

Background: Long-acting injectable (LAI) aripiprazole was found to be efficacious in schizophrenia. In common clinical practice, the use of LAIs is often restricted to chronic patients with frequent relapses and poor adherence. Recently, some investigators advanced the idea of early LAI use also in young people with schizophrenia at their first psychotic episode (FEP). Objective: Our study aimed to assess the effect of LAI aripiprazole once monthly (AOM) in the treatment of FEP in patients aged 18-26 years. Methods: We included 50 patients with DSM-5 schizophrenia as assessed with SCID, and used the Clinical Global Impressions Scale-Severity of Illness (CGI-S) and the Positive and Negative Syndrome Scale (PANSS) to assess symptom severity and the World Health Organization Quality of Life (WHOQOL), the Short Form Health Survey (SF-36) and the Personal and Social Performance Scale (PSP) to assess quality of life (QoL) and global health perception at baseline and 3, 6, 9, and 12 months after the first AOM injection. Results: AOM was associated with a progressive improvement, compared to baseline, of both positive (p < 0.001) and negative (p < 0.001) symptoms and in general psychopathology (p < 0.001) and decrease in global severity (p < 0.001). We also observed progressive improvement in QoL and social and personal functioning. Treatment adherence was 78% at study endpoint. Our results support that AOM may improve psychotic symptoms, QoL and social functioning in young FEP patients. Further studies should compare AOM to its oral formulation in the treatment of young patients with schizophrenia at the outset of their illness.

show abstract

Section: Other Issuesmentioning

confidence: 89%

Aripiprazole Long-Acting Injection During First Episode Schizophrenia—An Exploratory Analysis

Giordano¹,

Tomassini²,

Cuomo

et al. 2020

Front. Psychiatry

View full text Add to dashboard Cite

show abstract

“…P ro re nata (PRN) medications are commonly used to control aggressive behavior and other signs of emotional disturbance such as agitation, anxiety, and insomnia on psychiatric inpatient units. However, evidence to support the effectiveness of PRN medications is limited (Belgamwar and Fenton 2005;Srivastava 2009;Ahmed et al 2010;Molloy et al 2012;Douglas-Hall and Whicher 2015;Khokhar and Rathbone 2016;Zaman et al 2017;Ostinelli et al 2018Ostinelli et al , 2018, and in some cases, they may do more harm than good (Hilton and Whiteford 2008;Gaynes et al 2016). The data we do have about PRN effectiveness come mostly from studies that compare different PRN medications-rather than examining whether PRN use leads to better outcomes in the first place-or from retrospective reviews of patient outcomes (Gaynes et al 2016;Zaman et al 2017).…”

Section: Introductionmentioning

confidence: 99%

Pro Re NataMedication Use in Acute Care Adolescent Psychiatric Unit

Saito

Eng

Grosso

et al. 2020

Journal of Child and Adolescent Psychopharmacology

View full text Add to dashboard Cite

Objective: Evidence to support the use of pro re nata (PRN) medication is limited, and the details of PRN use (indication, frequency of administration, patient characteristics) are rarely reported, particularly in youth populations. The goal of this study was to report on the pattern of PRN use over 6 years in an acute care psychiatric unit for adolescents. Methods: A retrospective chart review of patients' records from November 2012 to October 2018 was conducted. Variables extracted from electronic medical records included age, gender, race/ethnicity, clinical rating scores at admission (on a subset of patients), length of stay, psychotropic and nonpsychotropic PRN medication administration, timing of administration, discharge diagnosis, and discharge medication. Results: Records from 2961 individuals with a total 3937 admissions were analyzed. A total of 62% of admissions had at least one PRN medication administration. Severity of symptoms, as indicated by higher scores on clinical rating scales at admission, longer length of stay, and readmission were related to high PRN use. Patients with bipolar spectrum disorders received more psychotropic and nonpsychotropic PRN medications than other patients. Patients who were high psychotropic PRN users were also high nonpsychotropic PRN users. Conclusion: Despite the lack of clear evidence in support of the efficacy of PRN medications, they commonly used to control symptoms in acute care inpatient settings. Youth with severe symptoms utilized not only psychotropic PRN medication but also nonpsychotropic PRN more frequently, suggesting a possible role of systemic disorder among youth with serious mental illness. More research is necessary to examine the efficacy of PRN medications for managing targeted symptoms.

show abstract

“…The 23 SRs, 24,25,29,31,32,34,35,37,38,40,41,43,44,46,47,[49][50][51][52][53][54][55][56] which all reported on CR drugs, and the umbrella SR, 28 were appraised for methodological quality using the JBI SR checklist. 22 T A B L E 1 Information on consent provided in the identified SRs, linked with the title of the review To estimate the effects of IM, oral-velotab, or standard oral olanzapine compared with placebo, haloperidol or lorazepam for controlling aggressive behaviour or agitation thought to be due to severe mental illness…”

Section: Critical Appraisalmentioning

confidence: 99%

Interrogating systematic review recommendations for effective chemical restraint

Muir‐Cochrane

Oster

Grimmer

2020

Evaluation Clinical Practice

View full text Add to dashboard Cite

Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation)

Abstract: Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation).

Cited by 25 publications

References 82 publications

Aripiprazole Long-Acting Injection During First Episode Schizophrenia—An Exploratory Analysis

Aripiprazole Long-Acting Injection During First Episode Schizophrenia—An Exploratory Analysis

Pro Re NataMedication Use in Acute Care Adolescent Psychiatric Unit

Interrogating systematic review recommendations for effective chemical restraint

Contact Info

Product

Resources

About